<DOC>
	<DOC>NCT00396279</DOC>
	<brief_summary>To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.</brief_summary>
	<brief_title>Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone</brief_title>
	<detailed_description />
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Giant Cell Tumor of Bone</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Adults, 18 years and older Histologically confirmed and measurable giant cell tumor (GCT) Recurrent GCT confirmed by radiology or unresectable GCT Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Pateints for whom surgery to the affected limb/area is planned within 27 days after receiving 1st dose of denosumab Radiation to affected region within 28 days before enrollment to study Known diagnosis of osteosarcoma or brown tumor of bone Known history of second malignancy within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ Concurrent treatment with bisphosphonates, calcitonin, or interferon. Other criteria also apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Giant Cell Tumor of Bone</keyword>
</DOC>